ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
ANAPTYSBIO, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
Anaptysbio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Market Cap | $1.47B | $166.30M |
| Enterprise Value | $1.31B | $87.12M |
| PS Ratio | 6.20 | 3.60 |
| PB Ratio | 139.07 | 2.03 |
| P/TBV Ratio | 139.07 | 2.31 |
| P/OCF Ratio | 81.41 | 13.32 |
Enterprise value
| Measure | Anaptysbio | Industry median |
|---|---|---|
| EV / Sales | 5.50 | 2.43 |
| EV / EBITDA | 4.18 | 14.69 |
| EV / EBIT | 4.18 | 18.47 |
Income (trailing twelve months)
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Revenue | $237.61M | $57.94M |
| Operating Income | $312.93M | -$21.49M |
| Pretax Income | $235.06M | -$14.72M |
| Net Income | $195.72M | -$22.46M |
| EBITDA | $312.95M | -$17.14M |
Margins
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Operating Margin | 131.7% | -44.5% |
| Pretax Margin | 98.9% | -13.0% |
| Profit Margin | 82.4% | -39.2% |
| EBITDA Margin | 131.7% | -31.3% |
Returns
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Return on Assets (ROA) | 60.0% | -41.0% |
| Return on Capital Employed (ROCE) | 111.1% | -38.0% |
Growth
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 92.9% | 6.01% |
| Revenue Growth (3Y CAGR) | 183.6% | 2.25% |
| Revenue Growth (5Y CAGR) | 25.6% | 6.42% |
Balance sheet
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $164.14M | $62.64M |
| Net Cash (Debt) | $164.14M | $15.77M |
| Net Cash Per Share | $5.49 | $0.66 |
| Equity (Book Value) | $10.59M | $48.61M |
| Book Value Per Share | $0.35 | $1.36 |
| Tangible Book Value | $10.59M | $23.01M |
| Working Capital | $163.07M | $75.09M |
Financial position
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Current Ratio | 5.61 | 3.30 |
| Quick Ratio | 5.37 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Operating Cash Flow | $18.08M | -$12.39M |
Efficiency
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Asset Turnover | 0.73 | 0.38 |
| Revenue Per Employee | $2.28M | $398.96K |
| Profits Per Employee | $1.88M | -$705.27K |
| Employee Count | 104 | 74 |
Dividends and yields
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Earnings Yield | 13.3% | -22.8% |
| Buyback Yield | -1.69% | -0.73% |
| Shareholder Yield | -1.69% | 0.00% |
Shares
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Shares Outstanding | 29,895,200 | 58,139,000 |
| Shares Change (YoY) | 11.5% | 11.1% |
| Shares Change (QoQ) | 2.40% | 0.54% |
| Float | 21,313,800 | 49,154,900 |
| Shares Held by Insiders | 28.7% | 11.6% |
| Shares Held by Institutions | 100.8% | 59.4% |
Taxes
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Income Tax | -$180.76M | $89.00K |
| Effective Tax Rate | -76.9% | 20.5% |
Scores
| Measure | Anaptysbio | Industry median |
|---|---|---|
| Altman Z-Score | 4.67 | -0.27 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Anaptysbio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.